HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Fujian Cancer Hospital, Fuzhou, Fujian

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

TianJin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality